Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

CHAPEL HILL, N.C., Jan. 12, 2011 /PRNewswire/ -- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12 in Washington D.C.  

Solithromycin is a clinical-stage fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, non-bacterial pathogens such as Plasmodium falciparum and a variety of bio-defense pathogens including Bacillus anthracis, Yersinia pestis, Burkholderia mallei and Francisella tularensis.  Phase 1 clinical studies with the oral formulation have shown excellent safety and tolerability and a pharmacokinetic profile that will enable once-daily dosing.  The oral formulation is undergoing a Phase 2 clinical trial in patients with community-acquired bacterial pneumonia (CABP).  An intravenous (IV) formulation of solithromycin is undergoing a safety and tolerability evaluation in a Phase 1 single and multiple dose escalation trial in healthy volunteers.  An oral pediatric suspension is also under development.

The presentation, delivered on January 12 by Jennifer Schranz, M.D., vice president of clinical affairs at Cempra Pharmaceuticals, described the potential utility of solithromycin as a bio-defense agent due to its broad antimicrobial spectrum, safety and tolerability, once-daily dosing, high tissue penetration, intracellular accumulation, and compound stability.  Data from mouse models were presented on the activity of once-daily solithromycin compared to an optimal dosing regimen of ciprofloxacin against B. anthracis and gentamicin against F. tularensis.  Solithromycin demonstrated activity comparable to c
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
3. Savient Pharmaceuticals Provides Business Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BioPharma Have Entered into an Agreement Under, Which Genmab Will ... ... USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February 21, ... ) announced today that they have entered into an agreement,under ...
... a,global provider of products and services that improve the ... by the New York,Department of Health for its public ... to maintain emergency response readiness, New,York has purchased more ... two years., Cardinal Health has already shipped 850 ...
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that Dr. Mark Nestor ... Symposium in Miami., In his presentation to ... attributes of Pyratine-6(TM) for the treatment of,photodamaged skin ...
Cached Biology Technology:Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 2Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 3
(Date:7/14/2014)... Is cancer an inevitable consequence of aging? , Although ... consequence of aging, the risk of developing several common ... puzzled by the apparent decrease with age in the ... possible solution to this puzzle was presented in a ... by Professor James P. Brody of the Department ...
(Date:7/13/2014)... COLUMBUS, Ohio A new study in women suggests ... before eating a single high-fat meal can slow the ... questioned study participants about the previous day,s stressors before ... 60 grams of fat. The scientists then measured their ... to burn calories and fat and took measures ...
(Date:7/11/2014)... fires burning in eastern New South Wales, Australia when ... At 03:35 UTC on July 11 (12:35 p.m. local ... over eastern New South Wales (NSW), the Moderate Resolution ... of the region and spotted smoke (light brown) from ... bands, are outlined in red. , The New South ...
Breaking Biology News(10 mins):Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... June 5, 2012 /PRNewswire-iReach/ -- Global Information ... discounted registration for three important international healthcare and biotechnology ... Antibody Engineering Summit 2012 November 6 ... Annual Protein & Antibody Engineering Summit (PEGS Europe) presents ...
... Ph.D., Wellcome Trust Principal Research Fellow and Head, ... of Emmanuel College, Cambridge, has been bestowed the ... recognizing exemplary leadership in the international microbiological community. ... of Virginia, says Smith is "internationally recognized as ...
... (June 6, 2012) Two studies appearing in the ... freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , evaluate the ... pancreatic tissues, in addition to a clinical study that ... islets are better than cultured islets , A ...
Cached Biology News:Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information 2Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information 3The American Society for Microbiology honors Geoffrey L. Smith 2Some factors that impact islet transplantation explored in Cell Transplantation papers 2Some factors that impact islet transplantation explored in Cell Transplantation papers 3Some factors that impact islet transplantation explored in Cell Transplantation papers 4
...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
Biology Products: